Date: 2017-01-19
Type of information: Capital increase
Company: PCI Biotech (Norway)
Investors:
Amount:
Funding type: capital increase
Planned used:
Others:
- • On January 19, 2017, PCI Biotech has announced that the share capital increase pertaining to the Rights Issue of 10,000,000 new shares, resolved by the extraordinary general meeting on 8 December 2016, has now been registered in the Norwegian Register of Business Enterprises, and the Rights Issue has thus been completed.
- PCI Biotech's new share capital is NOK 74,701,170 divided into 24,900,390 shares, each with a nominal value of NOK 3.00. The new shares issued in the Rights Issue will be tradable when they have been registered on the VPS accounts of the subscribers; such registration is expected to be executed 20 January 2017.
Therapeutic area: Cancer - Oncology
Is general: Yes
